Atossa Therapeutics Provides Enrollment Update For Ongoing Phase 2 Karisma-Endoxifen Clinical Trial; 170 Patients Have Been Enrolled In The Company's Ongoing Phase 2 Karisma-Endoxifen Clinical Trial. Atossa Expects The Study To Fully Enroll In Q4 2023
Portfolio Pulse from Happy Mohamed
Atossa Therapeutics, Inc. (NASDAQ:ATOS) has enrolled 170 patients in its ongoing Phase 2 Karisma-Endoxifen clinical trial, with full enrollment expected by Q4 2023. The trial is studying the efficacy of oral (Z)-endoxifen in premenopausal women with measurable breast density. The company's President and CEO, Dr. Steven Quay, expressed optimism about the potential of (Z)-endoxifen to reduce breast density and decrease the risk of breast cancer.
July 10, 2023 | 1:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Atossa Therapeutics is making progress in its Phase 2 Karisma-Endoxifen clinical trial, which could potentially lead to a new treatment for women with high breast density. Full enrollment is expected by Q4 2023.
The news of Atossa Therapeutics' progress in its Phase 2 Karisma-Endoxifen clinical trial is directly relevant to the company and its stock. If the trial proves successful, it could lead to a new treatment for women with high breast density, which could significantly boost the company's revenues and profitability. This could potentially lead to a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100